Comparing efficacy and tolerability of eperisone with thiocolchicoside in the management of non-specific low back pain

Ruchi Baghel; Sandeep Kumar Adwal; Vivek Singh; Rakesh Ranjan Pathak

doi:10.5455/njppp.2019.9.0931804102019

2026, Vol: 16, Issue: 2

16 / 2Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form
Title Page

« Previous Article

Original Research
Online Published: 19 Oct 2019

Natl J Physiol Pharm Pharmacol. 2019; 9(12): 1210-1215

doi: 10.5455/njppp.2019.9.0931804102019

Comparing efficacy and tolerability of eperisone with thiocolchicoside in the management of non-specific low back pain

Ruchi Baghel, Sandeep Kumar Adwal, Vivek Singh, Rakesh Ranjan Pathak.

Abstract
Background: Low back pain (LBP) afflicts 6080% of the people worldwide at some point in their lifetime. Association of spinal muscle spasm justifies centrally acting muscle relaxants in the treatment. Controversial superiority of eperisone visa-vis thiocolchicoside was instrumental to inception of this research.

Aims and Objectives: This study aims to compare the efficacy and safety of eperisone with thiocolchicoside in treatment of non-specific LBP.

Materials and Methods: This follow-up study was done in C. R. G. Hospital, Ujjain (India). Eligible 215 patients, of either sex, between 18 and 60 years from the outpatient orthopedic department were included and dysfunctional status was quantified by modified Oswestry Disability Index. The patients were given eperisone hydrochloride 100 mg 3 times daily or thiocolchicoside 8 mg twice daily. The analgesic activity and adverse drug reactions were evaluated on the follow-up visit after 7 days of treatment against the baseline.

Results: Of 196 patients who completed the study, females were more (119; 60.71%) than the male (77; 39.28%). Mean score ± standard deviation of disability decreased from 26.13 ± 8.28 at baseline to 11.47 ± 4.86 in eperisone group and from 24.78 ± 7.24 at baseline to 9.92 ± 3.63 in thiocolchicoside group. Change in the score against the baseline was statistically significant (P < 0.05) in both the groups but insignificant across the groups. Adverse events experienced were less with eperisone.

Conclusion: Compared to thiocolchicoside, eperisone hydrochloride is equipotent but better tolerated option in LBP.

Key words: Low Back Pain; Modified Oswestry Scale; Skeletal Muscle Relaxant; Thiocolchicoside; Eperisone

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Ruchi Baghel Articles by Sandeep Kumar Adwal Articles by Vivek Singh Articles by Rakesh Ranjan Pathak
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Baghel R, Adwal SK, Singh V, Pathak RR. Comparing efficacy and tolerability of eperisone with thiocolchicoside in the management of non-specific low back pain. Natl J Physiol Pharm Pharmacol. 2019; 9(12): 1210-1215.

doi:10.5455/njppp.2019.9.0931804102019

Web Style

Baghel R, Adwal SK, Singh V, Pathak RR. Comparing efficacy and tolerability of eperisone with thiocolchicoside in the management of non-specific low back pain. https://www.njppp.com/?mno=65511 [Access: June 27, 2026].

doi:10.5455/njppp.2019.9.0931804102019

AMA (American Medical Association) Style

Baghel R, Adwal SK, Singh V, Pathak RR. Comparing efficacy and tolerability of eperisone with thiocolchicoside in the management of non-specific low back pain. Natl J Physiol Pharm Pharmacol. 2019; 9(12): 1210-1215.

doi:10.5455/njppp.2019.9.0931804102019

Vancouver/ICMJE Style

Baghel R, Adwal SK, Singh V, Pathak RR. Comparing efficacy and tolerability of eperisone with thiocolchicoside in the management of non-specific low back pain. Natl J Physiol Pharm Pharmacol. (2019), [cited June 27, 2026]; 9(12): 1210-1215.

doi:10.5455/njppp.2019.9.0931804102019

Harvard Style

Baghel, R., Adwal, . S. K., Singh, . V. & Pathak, . R. R. (2019) Comparing efficacy and tolerability of eperisone with thiocolchicoside in the management of non-specific low back pain. Natl J Physiol Pharm Pharmacol, 9 (12), 1210-1215.

doi:10.5455/njppp.2019.9.0931804102019

Turabian Style

Baghel, Ruchi, Sandeep Kumar Adwal, Vivek Singh, and Rakesh Ranjan Pathak. 2019. Comparing efficacy and tolerability of eperisone with thiocolchicoside in the management of non-specific low back pain. National Journal of Physiology, Pharmacy and Pharmacology, 9 (12), 1210-1215.

doi:10.5455/njppp.2019.9.0931804102019

Chicago Style

Baghel, Ruchi, Sandeep Kumar Adwal, Vivek Singh, and Rakesh Ranjan Pathak. "Comparing efficacy and tolerability of eperisone with thiocolchicoside in the management of non-specific low back pain." National Journal of Physiology, Pharmacy and Pharmacology 9 (2019), 1210-1215.

doi:10.5455/njppp.2019.9.0931804102019

MLA (The Modern Language Association) Style

doi:10.5455/njppp.2019.9.0931804102019

APA (American Psychological Association) Style

doi:10.5455/njppp.2019.9.0931804102019

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article